News

CDC tuberculosis lead Dr. Phillip LoBue joins to discuss the past and present issues of the disease, in time for TB Awareness Day on March 24.

A single-injection co-formulation of pramlitide and insulin may be a better alternative to separate administrations of both key treatments in adults with T1D, particularly following meals.

A majority of surveyed patients and providers want to continue telemedicine follow-up visits after the pandemic ends.

Stimulating steroid receptor co-activators may play a role in repairing heart tissue following severe myocardial infarction.

In ENDO 2021 data, approximately one-third of an observed COVID-19 patient population in Italy was still experiencing signs of thyroid inflammation after 3 months,

Many patients with genetic obesity disorder experience resistance to treatment, including intensive lifestyle therapy.

Evening and late-night preferences of women with GDM is linked to a significantly greater risk of preeclampsia and NICU treatment.

A post-hoc analysis of the AWARD-11 trial indicates that 4.5 mg of dulaglutide was effective in lowering and maintaining A1C levels <7% regardless of baseline levels.

At the 76-week mark, reductions in the amyloid plaque level were 85.06 centiloids with donanemab than with placebo.

NAFLD can be common among those with diabetes or those who are obese.

An expert in dermatology discusses the potential impact of non-medical switching to biosimilars and generic formulations on safety and efficacy profiles.

Adam Friedman, MD, FAAD defines non-medical therapeutic switching and discusses common tactics payors use to pressure practitioners and patients to switch.

The approval is based on positive data from the Phase 3 RAPHSODY trial, which evaluated treatment in older children and adults.

Optimizing care and managing challenges for patients with ADHD during the COVID-19 pandemic and advice for clinicians educating patients and families on disease management.

Rakesh Jain, MD, MPH, shares his thoughts on whether drug holidays are appropriate for children taking medication for ADHD.

A discussion on the recent development of investigational serotonin norepinephrine modulating agent (SNMA), SPN-812, for the treatment of ADHD in adults.

Rakesh Jain, MD, MPH, considers the evidence-based recommended hierarchy in the choice of medications for the treatment of pediatric and adult ADHD.

Andrew J. Cutler, MD, reviews currently available stimulants and nonstimulants as well as their safety and efficacy for the treatment of ADHD.

Rakesh Jain, MD, MPH, shares his thoughts on the importance of combining pharmacological and non-pharmacological treatments for the management of ADHD.

Andrew J. Cutler, MD, discusses the benefits of cognitive behavior therapy (CBT), exercise, and family therapy for the management of ADHD.

Andrew J. Cutler, MD, and Rakesh Jain, MD, MPH, comment on comorbid psychiatric disorders complicating the diagnostic process for ADHD and review unmet needs.

A review of common signs and symptoms prompting testing for ADHD and approaching ADHD diagnosis in adults.

Updates in the AAP (American Academy of Pediatrics) and SDBP (Society for Developmental and Behavioral Pediatrics) guidelines for the assessment, evaluation, and treatment of ADHD in children and adolescents.

Telemedicine has allowed ADHD patients to continue care during the pandemic.

Some fear repeated injections of anti-VEGF drugs might harm retinal nerve fiber layer, but a new study finds little evidence of such harm.

The once-daily, 14-day, oral therapy is being investigated for fast-acting clinical response in patients with major depressive disorder or postpartum depression.

The majority of previous studies have focused on this link in the male population.

Patients with subjective vision changes should be referred for fundus examination.